Howden CW - Search Results

1

Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro-Oesophageal Reflux Disease or Erosive Oesophagitis.

Howden CW, Katz P, DeVault KR, Metz DC, Tamene D, Smith N, Hunt B, Chang YM, Spechler SJ. Howden CW, et al. Aliment Pharmacol Ther. 2024 Dec 25. doi: 10.1111/apt.18458. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 39720884

2

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, Shah SC. Chey WD, et al. Among authors: howden cw. Am J Gastroenterol. 2024 Sep 1;119(9):1730-1753. doi: 10.14309/ajg.0000000000002968. Epub 2024 Sep 4. Am J Gastroenterol. 2024. PMID: 39626064

3

Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon-HP trial.

Chey WD, Mégraud F, Laine L, Smith N, Leifke E, Hunt B, Howden CW. Chey WD, et al. Among authors: howden cw. JGH Open. 2024 Nov 15;8(11):e70044. doi: 10.1002/jgh3.70044. eCollection 2024 Nov. JGH Open. 2024. PMID: 39554983 Free PMC article.

4

The role of P-CABs in GERD.

Howden CW. Howden CW. Am J Gastroenterol. 2024 Oct 17. doi: 10.14309/ajg.0000000000003140. Online ahead of print. Am J Gastroenterol. 2024. PMID: 39466255

5

Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates.

Howden CW, Scarpignato C, Leifke E, Mulford DJ, Lahu G, Facius A, Yuan Y, Hunt R. Howden CW, et al. CPT Pharmacometrics Syst Pharmacol. 2024 Sep 19. doi: 10.1002/psp4.13235. Online ahead of print. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 39297248 Free article.

6

Re-evaluating the Proposed Association Between Vonoprazan and Gastric Cancer Following Eradication of H. pylori Infection.

Howden CW, Chey WD, Shah SC. Howden CW, et al. Clin Gastroenterol Hepatol. 2025 Jan;23(1):182-183. doi: 10.1016/j.cgh.2024.04.015. Epub 2024 May 8. Clin Gastroenterol Hepatol. 2025. PMID: 38729385 No abstract available.

7

Editorial: PPIs and gastric cancer-Are we dealing with a carcinogen?

Malfertheiner P, Schulz C, Howden CW. Malfertheiner P, et al. Among authors: howden cw. Aliment Pharmacol Ther. 2023 Nov;58(10):1099-1100. doi: 10.1111/apt.17691. Aliment Pharmacol Ther. 2023. PMID: 37885170 No abstract available.

8

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan.

Howden CW, Cook EE, Swallow E, Yang K, Guo H, Pelletier C, Jacob R, Sugano K. Howden CW, et al. Therap Adv Gastroenterol. 2023 May 2;16:17562848231168714. doi: 10.1177/17562848231168714. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 37153499 Free PMC article.

9

Physiologically-based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection.

Howden CW, Shah S, Pendse SN, Offman E, Almenoff JS, Sheldon KL. Howden CW, et al. Aliment Pharmacol Ther. 2023 Jul;58(2):159-167. doi: 10.1111/apt.17526. Epub 2023 Apr 20. Aliment Pharmacol Ther. 2023. PMID: 37081832

10

A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.

Scarpignato C, Howden CW, Leifke E, Mulford DJ, Lahu G, Facius A, Hunt R. Scarpignato C, et al. Among authors: howden cw. Aliment Pharmacol Ther. 2023 Jul;58(1):16-25. doi: 10.1111/apt.17510. Epub 2023 Apr 17. Aliment Pharmacol Ther. 2023. PMID: 37066678

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

321 results

Search Page

Filters